Stockreport

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dogwood Therapeutics, Inc.  (DWTX) 
PDF ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical-stage biopharmaceu [Read more]